Explore 3 Stock Ideas & Industry Insights Download Free Report
.png)
Meta Growth Corp. (TSXV: META) is a cannabis product retailer, which offers recreational cannabis products in Canada. The Company operates through its wide network of stores under the name of Meta Cannabis Co., Meta Cannabis Supply Co. and NewLeaf Cannabis.
Major Operational Highlights:
Q2FY20 Financial Highlights: META released its quarterly numbers wherein the company’s revenue declined ~16% to CAD 13.6 million from CAD 16.20 million in the previous corresponding period. Gross profit decreased to CAD 9.51 million as compared to CAD 10.97 million, primarily attributable to lower sales, partially offset by a decline in the cost of sales. The Group reported a slightly lower net loss of CAD 5.543 million, as compared to CAD 5.643 million in the previous corresponding period. The Company posted a cash balance of CAD 15.7 million, significantly higher than CAD 8.9 million in the previous quarter.

Q2FY20 Financial Snapshot (Source: Company Reports)
Stock Recommendation: The stock of META soared ~33% in the last one month and currently trading at CAD 0.12 with a market capitalization of CAD 28.4 million. The stock has corrected ~82% in last one year and ~63% so far this year. The group’s second quarter result failed to impress as the revenue and gross profit declined significantly. The group operates in market where the competition is fierce, and the group has not opened any new stores in Alberta during the quarter. The group is planning to open stores in other provinces and granted Cannabis Retail Operator License in Ontario but making inroads to the new markets are always challenging. The group seems to have a decent liquidity and added an unsecured loan drawdown facility of CAD 11 million, to support its near-term operations, but rising debt poses a concern. The group has ~31 million as outstanding debt (term loan and debenture) at the end of Q2FY20. The group is strengthening its online channel which is likely to drive revenue in the near term. The stock is trading at lower EV/Sales multiple of 0.2x on TTM basis as compared to the industry (Pharmaceuticals) median of 4.9x. We believe the lower multiple is justified given the group’s dismal performance. Hence, we prefer to remain on the sideline and recommend a ‘Watch’ stance on the stock at the closing market price of CAD 0.12, as on May 22, 2020.

META Daily Technical Chart (Source: Refinitiv, Thomson Reuters)
Disclaimer
The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.
Past performance is not a reliable indicator of future performance.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Start Your 7-Days Free Trial Today!